Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Rating of “Buy” from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned a consensus recommendation of “Buy” from the nine ratings firms that are presently covering the firm, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $60.8571.

KNSA has been the topic of several research analyst reports. Wells Fargo & Company lifted their price target on Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Zacks Research raised Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, June 17th. Citigroup raised their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Jefferies Financial Group raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $59.49 on Wednesday. Kiniksa Pharmaceuticals International has a 1 year low of $26.27 and a 1 year high of $59.94. The stock has a market cap of $4.58 billion, a PE ratio of 66.10 and a beta of 0.12. The business’s fifty day moving average is $51.46 and its 200-day moving average is $46.63.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same period last year, the firm earned $0.11 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. Equities research analysts predict that Kiniksa Pharmaceuticals International will post 1.24 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the completion of the sale, the chief executive officer directly owned 48,565 shares of the company’s stock, valued at approximately $2,623,481.30. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares of the company’s stock, valued at $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 653,301 shares of company stock valued at $34,046,073. Corporate insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares during the period. Janus Henderson Group PLC boosted its position in shares of Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock worth $23,197,000 after buying an additional 327,595 shares during the period. California State Teachers Retirement System boosted its position in shares of Kiniksa Pharmaceuticals International by 33.3% in the first quarter. California State Teachers Retirement System now owns 41,975 shares of the company’s stock worth $2,021,000 after buying an additional 10,477 shares during the period. Rubric Capital Management LP boosted its position in shares of Kiniksa Pharmaceuticals International by 12.7% in the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Kiniksa Pharmaceuticals International by 56.7% in the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock worth $3,050,000 after buying an additional 22,917 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.